Source-grounded facts extracted from KIORA PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
KIORA PHARMACEUTICALS INC reported financial results for the first quarter ended March 31, 2026.
“On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress.”
KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at expected aggregate gross proceeds at closing of approximately $5.0 million and potential future warr (effective 2026-04-03).
“On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”),”
KIORA PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $16.0 million, net income $13.5 million.
“Revenue was $16.0 million for the first quarter of 2024, compared to no revenue in the first quarter of 2023. The revenue comes from collaboration revenue as part of an upfront payment from TOI connected to the strategic development and commercialization partnership. Research and development expenses were $1.5 million, net of $0.2 million in offsetting credits related to expenses for KIO-301 which will be reimbursed by TOI, for the first quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily due to a one-time licensing payment made to the University of California related to a sublicense fee of $0.7 million, and a decrease of $0.3 million in R&D tax credits due to reduced credit-eligible expenses given the KIO-301 expenses are now being reimbursed by TOI. General and administrative expenses were $1.3 million for the first quarter of 2024, compared to $1.3 million for the first quarter of 2023. N”
KIORA PHARMACEUTICALS INC shareholders approved Approval of the Adjournment of the Annual Meeting, If Necessary, to Solicit Additional Proxies at the 2024-05-01 meeting.
“The adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of any of the forgoing proposals at the time of the annual meeting was approved. However, the Company elected not to adjourn the meeting to solicit additional proxies for Proposal 4. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 17,206,128 377,890 16,544 2,990,721”
KIORA PHARMACEUTICALS INC shareholders approved Ratification of the Appointment of Haskell & White LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-05-01 meeting.
“The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified. There were no broker non-votes on this proposal. The results of the vote were as follows: Votes For Votes Against Votes Abstained 18,896,438 1,622,946 71,899”
KIORA PHARMACEUTICALS INC shareholders approved Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2024-05-01 meeting.
“The compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with respect to the Annual Meeting was approved on a non-binding basis. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,291,900 1,224,207 84,455 2,990,721”
KIORA PHARMACEUTICALS INC shareholders approved Approval of the Issuance of up to 49,374,590 Shares of Common Stock Upon the Exercise of Tranche A Warrants and Tranche B Warrants at the 2024-05-01 meeting.
“The issuance, as contemplated by Nasdaq Listing Rule 5635, of up to 49,374,590 shares of Common Stock upon the exercise of Tranche A Warrants and Tranche B Warrants issued in a private placement completed in February 2024 was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,266,989 1,317,078 16,495 2,990,721”
KIORA PHARMACEUTICALS INC shareholders approved Approval of the Company's 2024 Equity Incentive Plan at the 2024-05-01 meeting.
“The Company’s 2024 Equity Incentive Plan was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,153,997 1,360,851 85,714 2,990,721”
KIORA PHARMACEUTICALS INC shareholders rejected Approval of an Amendment to Restated Certificate of Incorporation to Adjust Voting Requirements for Certain Future Amendments at the 2024-05-01 meeting.
“An amendment to the Company’s Restated Certificate of Incorporation to adjust voting requirements for certain future amendments was not approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,329,852 1,254,063 16,647 2,990,721”
KIORA PHARMACEUTICALS INC shareholders approved Approval of an Amendment to Restated Certificate of Incorporation to Increase Authorized Shares of Common Stock to 150,000,000 at the 2024-05-01 meeting.
“An amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to 150,000,000 was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,088,708 1,506,157 5,697 2,990,721”
KIORA PHARMACEUTICALS INC shareholders approved Approval of an Amendment of Our Restated Certificate of Incorporation to Effect a Reverse Stock Split at the 2024-05-01 meeting.
“An amendment to the Company’s Restated Certificate of Incorporation to effect a Reverse Stock Split of the shares of Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-10, with the exact ratio of, effective time of and decision to implement the Reverse Stock Split to be determined by the Company’s Board of Directors was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained 18,297,948 2,258,164 35,171”
KIORA PHARMACEUTICALS INC shareholders approved Election of David Hollander, MD, MBA and Erin Parsons as Class III Directors at the 2024-05-01 meeting.
“David Hollander, MD, MBA and Erin Parsons were elected as Class III Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such directors’ successors are duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes David Hollander, MD, MBA 16,555,192 1,045,370 2,990,721 Erin Parsons 16,478,582 1,121,980 2,990,721”
KIORA PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.
“Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.